Maria D Lozano1,2,3, Marta Abengozar-Muela1, José I Echeveste1, José Carlos Subtil4, Juan Bertó5, Alfonso Gúrpide6, Alfonso Calvo3,7,8, Carlos E de Andrea1,2,3,8. 1. Department of Pathology, University of Navarra Clinic, University of Navarra, Pamplona, Spain. 2. CIBERONC, Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. 3. Health Research Institute of Navarra (IDISNA), Pamplona, Spain. 4. Department of Gastroenterology, University of Navarra Clinic, University of Navarra, Pamplona, Spain. 5. Pulmonary Department, University of Navarra Clinic, University of Navarra, Pamplona, Spain. 6. Department of Medical Oncology, University of Navarra Clinic, University of Navarra, Pamplona, Spain. 7. Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. 8. Department of Histology and Pathology, University of Navarra, Pamplona, Spain.
Abstract
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non-small cell lung cancer (NSCLC) for anti-programmed cell death protein 1 (PD-1)/PD-L1 therapy. The current study evaluated the feasibility and efficacy of PD-L1 immunostaining and quantitation on direct Papanicolaou-stained cytological smears compared with formalin-fixed paraffin-embedded samples (cytological cell blocks and surgical resection specimens) in NSCLC cases using 2 commercially available assays: the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies/Dako, Carpinteria, CA, USA) and the Ventana SP263 Assay (Ventana Medical Systems Inc, Tucson, Arizona). METHODS: PD-L1 immunostaining using either both or one of the assays was tested in 117 sets of paired samples obtained from 62 NSCLC cases. The tumor proportion score was reported in every case following the recommendations of the International Association for the Study of Lung Cancer (IASLC). RESULTS: In 57 sets of samples, both PD-L1 assays were used. Due to the availability of samples, only 1 assay was performed in 3 sets of samples and in 2 cases, only cytology smears were used and tested for both assays. A total of 113 sets of paired samples finally were evaluated; 4 cases could not be studied due to intense nonspecific background staining. A significant concordance between the 2 assays on cytological smears was found. Concordance between paired cytological smears and formalin-fixed paraffin-embedded samples was observed in 97.3% of the cases. CONCLUSIONS: The quantification of PD-L1 expression on direct Papanicolaou-stained cytology smears is feasible and reliable for both PD-L1 assays.
BACKGROUND:Programmed death-ligand 1 (PD-L1) expression, as assessed by immunohistochemistry (IHC), is used to select patients with non-small cell lung cancer (NSCLC) for anti-programmed cell death protein 1 (PD-1)/PD-L1 therapy. The current study evaluated the feasibility and efficacy of PD-L1 immunostaining and quantitation on direct Papanicolaou-stained cytological smears compared with formalin-fixed paraffin-embedded samples (cytological cell blocks and surgical resection specimens) in NSCLC cases using 2 commercially available assays: the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies/Dako, Carpinteria, CA, USA) and the Ventana SP263 Assay (Ventana Medical Systems Inc, Tucson, Arizona). METHODS:PD-L1 immunostaining using either both or one of the assays was tested in 117 sets of paired samples obtained from 62 NSCLC cases. The tumor proportion score was reported in every case following the recommendations of the International Association for the Study of Lung Cancer (IASLC). RESULTS: In 57 sets of samples, both PD-L1 assays were used. Due to the availability of samples, only 1 assay was performed in 3 sets of samples and in 2 cases, only cytology smears were used and tested for both assays. A total of 113 sets of paired samples finally were evaluated; 4 cases could not be studied due to intense nonspecific background staining. A significant concordance between the 2 assays on cytological smears was found. Concordance between paired cytological smears and formalin-fixed paraffin-embedded samples was observed in 97.3% of the cases. CONCLUSIONS: The quantification of PD-L1 expression on direct Papanicolaou-stained cytology smears is feasible and reliable for both PD-L1 assays.
Authors: Mari Mino-Kenudson; Nolwenn Le Stang; Jillian B Daigneault; Andrew G Nicholson; Wendy A Cooper; Anja C Roden; Andre L Moreira; Erik Thunnissen; Mauro Papotti; Giuseppe Pelosi; Noriko Motoi; Claudia Poleri; Elisabeth Brambilla; Mary Redman; Deepali Jain; Sanja Dacic; Yasushi Yatabe; Ming Sound Tsao; Fernando Lopez-Rios; Johan Botling; Gang Chen; Teh-Ying Chou; Fred R Hirsch; Mary Beth Beasley; Alain Borczuk; Lukas Bubendorf; Jin-Haeng Chung; David Hwang; Dongmei Lin; John Longshore; Masayuki Noguchi; Natasha Rekhtman; Lynette Sholl; William Travis; Akihiko Yoshida; Murry W Wynes; Ignacio I Wistuba; Keith M Kerr; Sylvie Lantuejoul Journal: J Thorac Oncol Date: 2021-03-02 Impact factor: 20.121
Authors: Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström Journal: Acta Cytol Date: 2021-07-07 Impact factor: 2.319